Oral and Esophageal Brush Biopsy
Customize your policy alerts
Sign up for Aetna Policy 0686 alerts
Get alerted when Policy 0686 changes without checking for updates manually.
Monitor payer policy activity
Defines Aetna's coverage stance for oral and esophageal brush biopsy techniques (including OralCDx, WATS3D/EndoCDx, DNA/RNA-based tests and esophageal balloon sampling) for screening, diagnosis, and surveillance of oral and esophageal lesions; affects providers submitting claims to Aetna.
No material clinical or coverage changes in this revision.
Coverage Criteria
Experimental and Investigational
Aetna considers the following procedures experimental and investigational because effectiveness has not been established:
These procedures are considered experimental/investigational and not established for screening, diagnosis or surveillance of cancerous or pre-cancerous lesions.
General coverage criteria
Coverage stance based on available evidence:
Supported by systematic reviews and guideline statements noting limited high-quality evidence and that adjunctive tests cannot replace tissue diagnosis.
Brush 'biopsy' sampling cannot provide a definitive histologic diagnosis and positive/abnormal adjunctive results require confirmatory tissue biopsy.
Evidence summaries relevant to coverage
Summary of coverage-relevant evidence and contexts
Evidence includes systematic reviews and cohort studies with methodological limitations (small samples, retrospective designs).
Guideline statements emphasize diagnostic-yield data and rate the evidence as low quality for outcome benefit.
Adjunctive use supported with limitations
Evidence and guideline-supported scenarios from the provided text
Adjunctive increases in detection reported in community and referral series but clinical significance and long‑term outcomes remain uncertain.
These limitations support a cautious or conditional stance for adjunctive use.
Supports adjunctive use but indicates uncertainty about effect on patient outcomes.
Adjunctive use with forceps biopsy
Evidence supports use of WATS-3D as an adjunct to white light endoscopy with Seattle protocol forceps biopsy in selected populations, with variable strength depending on dysplasia prevalence.
ASGE gives a conditional recommendation based on low-quality evidence; adjunctive use increases detection but downstream outcome benefit is unproven.
Substitution or standalone use
Evidence for WATS-3D as a substitute for forceps biopsy or as standalone testing is limited and inconsistent.
Further prospective studies are needed before recommending routine standalone use.
Evidence-summary coverage considerations
Summary of evidence-based coverage implications from reviewed studies:
Clinical significance and management impact of additional detections require further study and confirmation.
Combination of methods increases procedure time versus single modality.
Positive adjunctive results in clinically suspicious lesions require confirmatory scalpel biopsy.
Evidence level is low; further clinical studies required.
Aetna considers several brush-based and related transepithelial sampling techniques experimental and investigational because their effectiveness for screening, diagnosis, or surveillance of oral or esophageal cancer has not been established. These include Oral brush biopsy (OralCDx Brush Test) (with or without MAGE‑A or GLUT‑1 staining), esophageal brush biopsy (WATS‑3D/EndoCDx), DNA‑image cytometry of brush specimens, RNA‑based oral brush biopsy, and use of an esophageal balloon for circumferential cytologic sampling. These procedures are considered not established for routine clinical use for screening, diagnosis, or surveillance of cancerous or pre‑cancerous lesions.
Brush cytology techniques (oral or esophageal) cannot provide a definitive histologic diagnosis because they sample cells rather than intact tissue; therefore a positive or suspicious brush result must be confirmed with a scalpel (tissue) biopsy and histopathology before establishing a diagnosis or directing definitive therapy.
Major society guidelines (including the American Gastroenterological Association, the American College of Gastroenterology, the British Society of Gastroenterology, and Cancer Council Australia) do not recommend brush biopsy for Barrett’s esophagus screening or routine surveillance. Guideline statements emphasize that brush biopsy techniques have not been established as standard screening or surveillance tools for Barrett’s esophagus.
Available evidence does not establish that WATS‑3D can reliably substitute for the Seattle protocol 4‑quadrant random forceps biopsy. Randomized and cohort studies were generally designed to evaluate WATS‑3D as an adjunctive technique or compared modalities without demonstrating consistent superiority of WATS‑3D as a standalone replacement for standard sampling.
Although WATS‑3D increases the number of dysplasia diagnoses in many series, the clinical significance of additional detections (for example, dysplasia found only by WATS, crypt dysplasia, or cases reported as indefinite for dysplasia) is uncertain. Studies have limited long‑term outcome data and variable pathologic confirmation, so the impact of these additional findings on patient outcomes is not well defined.
The policy excerpts do not list explicit payer exclusions beyond designation of the listed procedures as experimental/investigational, but note important limitations—such as lack of centralized pathology concordance, limited long‑term follow‑up, variable dysplasia definitions, and potential industry sponsorship—that argue for cautious interpretation before covering WATS‑3D or related brush techniques as standalone replacements for standard care.
This Clinical Policy Bulletin is intended as informational guidance to assist in administering plan benefits. It is a partial description of benefits and does not constitute a contract; specific plan documents and coverage determinations govern actual coverage decisions.
There is insufficient evidence to support use of oral brush biopsy as a routine general screening test for oral cancer or potentially premalignant oral lesions. Systematic reviews and guideline statements conclude that brush cytology is an adjunctive screening tool at best, and positive or suspicious results require confirmatory scalpel biopsy.
Routine population‑based screening using adjunctive technologies (including brush biopsy, toluidine blue, or fluorescence imaging) is not supported by robust randomized trial evidence to demonstrate a reduction in oral cancer mortality, except for limited findings in select high‑risk subgroups; therefore routine population screening with these adjuncts is not supported.
Randomized and comparative data do not support routine replacement of the Seattle protocol forceps biopsy with WATS‑3D. Where studied, WATS‑3D has generally been evaluated as an adjunct to white‑light endoscopy with Seattle protocol biopsies rather than as a proven standalone alternative.
Using WATS‑3D as the sole surveillance technique without confirmation by forceps biopsy has not been established. Studies that report WATS‑only dysplasia often lack routine confirmatory histology and have limited follow‑up, so the diagnostic validity and longitudinal implications of WATS‑only findings remain unproven.
WATS‑3D results alone should not routinely be used to direct definitive management in place of confirmatory forceps biopsy histology. Randomized data from enriched cohorts did not show WATS‑3D alone to be superior to forceps biopsy for detection of high‑grade dysplasia or esophageal adenocarcinoma, so forceps biopsy and histology remain the primary basis for management decisions.
Randomized data in enriched Barrett’s esophagus populations did not demonstrate that WATS‑3D alone is superior to forceps biopsy for detecting high‑grade dysplasia or esophageal adenocarcinoma. Given those findings, forceps biopsy using the Seattle protocol is considered the primary sampling method, with WATS‑3D considered adjunctive rather than a routine replacement.
Coding
| 88104 | Cytopathology, fluids, washings or brushings, except cervical or vaginal; smears with interpretation. |
| 99000 | Handling and/or conveyance of specimen for transfer from the physician's office to a laboratory. |
| 40808 | Biopsy, vestibule of mouth. |
| 41108 | Biopsy of floor of mouth. |
| 42800 | Biopsy; oropharynx. |
| 42804 | nasopharynx, visible lesion, simple. |
| 42806 | nasopharynx, survey for unknown primary lesion. |
| 43191 | Esophagoscopy, rigid, transoral; diagnostic, including collection of specimen(s) by brushing or washing when performed (separate procedure). |
| 43200 | Esophagoscopy, flexible, transoral; diagnostic, including collection of specimen(s) by brushing or washing, when performed (separate procedure). |
| 88160 | Cytopathology smears, any other source; screening and interpretation. |
| D0486 | Laboratory accession of transepithelial cytologic sample, microscopic examination, preparation and transmission of written report. |
| D7288 | Brush biopsy - transepithelial sample collection. |
| D7287 | Exfoliative cytological sample collection. |
| D00.00 - D00.08 | Carcinoma in situ of lip, oral cavity, and pharynx. |
| D10.0 - D11.9 | Benign neoplasm of mouth, pharynx and major salivary glands. |
| D37.01 - D37.02, D37.04 - D37.09 | Neoplasm of uncertain behavior of lip, oral cavity, and pharynx. |
| K09.1 - K09.9 | Cysts of oral region, not elsewhere classified. |
| K12.0 - K13.79 | Stomatitis and related lesions and other diseases of lip and oral mucosa. |
| K14.0 - K14.9 | Diseases of tongue. |
| Z12.81 | Encounter for screening for malignant neoplasm of oral cavity. |
| not provided | No explicit CPT/ICD codes listed in this document fragment. |
| affected codes | WATS3D / brush biopsy procedure codes referenced as affected by policy (document lists 'affected codes' placeholder) |
| not specified | The provided document excerpt does not list CPT/HCPCS/ICD codes for WATS-3D or brush biopsy. |
| No codes listed |
Provider Actions & Billing Notes
Coding reference and billing notes
Providers should reference the code groups below when submitting authorization requests or claims. Codes specific to oral or esophageal brush cytology that are listed as experimental/investigational should be submitted with appropriate clinical justification; claims relying solely on brush cytology without confirmatory tissue biopsy may be challenged or denied.
- CPT/HCPCS/ICD-10 coding reference (see code table for detailed lists).
- Claims based only on brush biopsy cytology (no scalpel/forceps tissue biopsy) lack histologic confirmation and may be denied.
- When brush methods are billed adjunctively to standard biopsies, include both sets of results in the record.
Prior Authorization — adjunctive and substitution use
Prior authorization (PA) may be required when adding WATS-3D (esophageal brush biopsy) to standard forceps biopsy, or when proposing WATS-3D as a replacement for forceps biopsy (FB). When requesting PA, clearly state whether WATS-3D is being used as an adjunct to FB or proposed as a substitution, and provide rationale and relevant clinical history (e.g., prior dysplasia, prior non-diagnostic FB, extent of Barrett’s segment).
- PA more likely when WATS-3D is proposed instead of the Seattle protocol FB.
- If PA is requested for adjunctive WATS-3D use, document why adjunctive sampling is necessary (e.g., prior negative FB with persistent clinical suspicion).
Clinical documentation and follow-up
Document the intended role of any brush-based test in the clinical encounter: whether it is an adjunct to forceps biopsy, a screening tool, or proposed as a replacement. Include the conventional oral exam or white-light endoscopic assessment findings, rationale for adjunctive testing, and how the brush result informed management.
- Record conventional oral examination (COE) or white light endoscopy (WLE) findings and any focal/suspicious lesion descriptions prior to adjunctive testing.
- For adjunctive WATS-3D, document whether the Seattle protocol or targeted biopsies were performed and the order of procedures (WATS vs FB).
- When brush testing is adjunctive, include both brush cytology results and corresponding FB histology in the chart.
- If brush cytology is positive, document plans for confirmatory scalpel/forceps biopsy (definitive diagnostic step).
Adjunctive use documentation recommended
Adjunctive testing should be accompanied by specific documentation to support its use and to permit accurate adjudication: indication for adjunctive testing, prior biopsy history, presence or absence of focal lesions, adherence to Seattle protocol (for BE), and the impact of adjunctive results on clinical management.
- When WATS-3D is used adjunctively, document how the additional findings changed surveillance intervals or triggered therapy.
- Specify whether targeted biopsies of suspicious areas were obtained and placed in separate pathology containers.
- Include correspondence or records of any downstream management decisions (surveillance enrollment, increased surveillance frequency, initiation of ablation, PPI changes) prompted by WATS findings.
Specimen handling and pathology review
Specimen handling and pathology review differ between modalities and should be documented. WATS-3D specimens are generally analyzed centrally (CDx laboratory) while forceps biopsy specimens are reviewed by institutional pathologists; when discrepant results occur, note any secondary/central pathology review and reconciliation steps.
- Ship WATS-3D specimens per manufacturer's/central lab instructions and document chain of custody/handling.
- Document whether forceps biopsy slides underwent local and/or central expert re-review, especially when WATS and FB results disagree.
- If pathology discrepancy exceeds local thresholds (e.g., >10% discordance in some studies), document whether central confirmation was sought.
Document concurrent FB and WATS-3D results and resultant management
Document concurrent FB and WATS-3D results and the resultant management decisions. Records should show how discordant results were reconciled and whether positive brush findings prompted confirmatory tissue biopsy or changes in surveillance/therapy.
- When FB is negative but WATS-3D is positive, document subsequent confirmatory steps taken (repeat FB, targeted biopsy, expert pathology review).
- Capture management actions resulting from WATS-3D findings (e.g., enrollment in surveillance, initiation/increase of PPI therapy, referral for ablation).
Evidence and outcome considerations
Recognize and document limitations of the evidence. Increased diagnostic yield with WATS-3D has been demonstrated in multiple studies, but whether this translates to improved patient outcomes remains uncertain; evidence quality has been rated low to inconsistent in guidelines.
- Note in the medical record when WATS-3D is being used despite limited evidence for outcome benefit.
- When relying on registry or single-center data to support use, document study limitations and applicability to the patient’s setting.
Experimental/Investigational exclusions
Brush-based tests listed as experimental/investigational per this policy should be recognized as such in requests and claims. Procedures considered experimental/investigational may be excluded from coverage.
- OralCDx brush test and other RNA/DNA-based brush assays are listed as experimental/investigational.
- Esophageal brush biopsy (WATS3D/EndoCDx) is listed in the Experimental/Investigational section for certain indications — check policy specifics.
- Use of esophageal balloon sampling for circumferential cytology is considered experimental/investigational.
Confirmatory diagnostic step required
A tissue biopsy (scalpel or forceps biopsy) remains the diagnostic standard. Positive brush cytology results should prompt confirmatory tissue biopsy because cytology alone cannot provide histologic diagnosis required for definitive management.
- Claims or prior authorization requests relying solely on brush cytology without confirmatory tissue biopsy should include medical justification; absence of histologic confirmation may lead to denial.
- When a brush test is positive for dysplasia or malignancy, document the plan and timing for confirmatory forceps/scalpel biopsy.
Preferred evaluation sequence; adjunct before replacement
Providers should follow a preferred evaluation sequence: perform a conventional oral exam or white-light endoscopic assessment first, obtain targeted forceps biopsies of suspicious lesions (Seattle protocol/random 4-quadrant FB for BE) as the initial diagnostic sampling, and reserve brush cytology or WATS-3D for adjunctive use when indicated. WATS-3D was primarily studied as an adjunct, not a replacement, so stepwise use (FB first, adjunctive WATS as needed) is recommended.
- Adjunctive testing is appropriate when FB is non-diagnostic or when there is persistent clinical concern despite negative FBs.
- Do not use WATS-3D routinely as a substitute for FB without prior authorization and strong clinical justification.
Documentation completeness and protocol adherence
Lack of adherence to standard biopsy protocols (e.g., Seattle protocol) or incomplete documentation of indications and focal lesions can bias comparisons between FB and WATS-3D and may affect coverage decisions. Ensure documentation of adherence to biopsy protocols and completeness of clinical data.
- Document whether the Seattle protocol or appropriate 4-quadrant sampling was performed and any deviations from protocol.
- If data are incomplete (e.g., missing indication, segment length, prior dysplasia history), state this in requests and provide available supplementary records.
Policy scope and provider responsibilities
Clinical Policy Bulletins are informational and provide a partial description of benefits; they do not constitute a contract. Providers remain responsible for clinical decisions and for obtaining benefit verification and any required prior authorization.
- Confirm member-specific coverage and PA requirements with the payer prior to performing procedures.
- This CPB does not replace plan documents — use plan benefits and authorizations to determine coverage.
Background
Scalpel (tissue) biopsy is the definitive diagnostic method for oral mucosal lesions. Brush biopsy techniques were developed as less invasive adjunctive methods to sample epithelial layers, but they detect cellular atypia rather than provide histologic architecture; therefore positive brush results require confirmation with scalpel biopsy and histopathology for a definitive diagnosis.
Definitions
Revision History
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.